Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course

Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course

Background: In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) concentrations and its association with immunotherapy and disease course in two independent MS cohorts. Methods: In our retrospective cross-sec...

Full description

Bibliographic Details
Main Authors:	Greta Zoehner, Andrei Miclea, Anke Salmen, Nicole Kamber, Lara Diem, Christoph Friedli, Maud Bagnoud, Farhad Ahmadi, Myriam Briner, Nazanin Sédille-Mostafaie, Constantinos Kilidireas, Leonidas Stefanis, Andrew Chan, Robert Hoepner, Maria Eleftheria Evangelopoulos
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-09-01
Series:	Therapeutic Advances in Neurological Disorders
Online Access:	https://doi.org/10.1177/1756286419878340

Similar Items

Prediction of conversion to multiple sclerosis using the 2017 McDonald and 2016 MAGNIMS criteria in patients with clinically isolated syndrome: a retrospective single-centre study
by: Andrei Miclea, et al.
Published: (2019-03-01)

An algorithm using clinical data to predict the optimal individual glucocorticoid dosage to treat multiple sclerosis relapses
by: Judit Gili-Kovács, et al.
Published: (2021-06-01)

c-Jun N-Terminal Kinase as a Therapeutic Target in Experimental Autoimmune Encephalomyelitis
by: Maud Bagnoud, et al.
Published: (2020-09-01)

Moyamoya Disease May Mimic Multiple Sclerosis?
by: Ioanna Spanou, et al.
Published: (2019-01-01)

Negative SARS-CoV2-antibodies after positive COVID-19-PCR nasopharyngeal swab in patients treated with anti-CD20 therapies
by: Christoph Friedli, et al.
Published: (2021-05-01)

Comparison of mRNA Vaccinations with BNT162b2 or mRNA-1273 in Anti-CD20-Treated Multiple Sclerosis Patients
by: Helly Hammer, et al.
Published: (2022-06-01)

Specific myeloid signatures in peripheral blood differentiate active and rare clinical phenotypes of multiple sclerosis
by: Aigli G. Vakrakou, et al.
Published: (2023-01-01)

In Vivo and In Vitro Evidence for an Interplay between the Glucocorticoid Receptor and the Vitamin D Receptor Signaling
by: Maud Bagnoud, et al.
Published: (2023-09-01)

Predicting conversion to multiple sclerosis in patients with radiologically isolated syndrome: a retrospective study
by: Panagiotis Chaloulos-Iakovidis, et al.
Published: (2021-07-01)

Pathological cerebrospinal fluid protein concentration and albumin quotient at relapse predicts short-term disability progression in multiple sclerosis: a retrospective single center observational study
by: Lara Diem, et al.
Published: (2020-12-01)

Editorial: Demyelinating neurological syndromes: The role of autoimmunity
by: Maria Eleftheria Evangelopoulos, et al.
Published: (2023-03-01)

Waning Humoral Immune Response to SARS-CoV-2 Vaccination with Symptomatic Infection after Initiation of Anti-CD20 Treatment in a Patient with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2022-03-01)

Central Nervous System Demyelination in a Charcot-Marie-Tooth Type 1A Patient
by: Christos Koros, et al.
Published: (2013-01-01)

Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases
by: Aigli G. Vakrakou, et al.
Published: (2022-03-01)

Sex differences in multiple sclerosis relapse presentation and outcome: a retrospective, monocentric study of 134 relapse events
by: Pauline Thränhardt, et al.
Published: (2024-03-01)

No optical coherence tomography changes in premanifest Huntington's disease mutation carriers far from disease onset
by: Rahel Dominique Schmid, et al.
Published: (2022-06-01)

COVID-19 in a Neuroimmunological Outpatient Cohort: The Bernese Experience
by: Maximilian Pistor, et al.
Published: (2022-02-01)

The impact of immunotherapies on COVID-19 case fatality rates during the US vaccination campaign: a multidisciplinary open data analysis using FDA Adverse Event Reporting System and Our World in Data
by: Anke Salmen, et al.
Published: (2023-06-01)

Alemtuzumab-induced alopecia universalis and transient accommodation spasm in a patient with multiple sclerosis
by: Dimitrios Tzanetakos, et al.
Published: (2022-10-01)

An Updated Evaluation of Intrathecal IgG Synthesis Markers in Relation to Oligoclonal Bands
by: Fotini Boufidou, et al.
Published: (2023-01-01)

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature
by: E. Andreadou, et al.
Published: (2013-01-01)

Clinico-radiologic features and therapeutic strategies in tumefactive demyelination: a retrospective analysis of 50 consecutive cases
by: Aigli G. Vakrakou, et al.
Published: (2021-05-01)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2014-01-01)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
by: Robert Hoepner, et al.
Published: (2014-04-01)

Differentiating central nervous system demyelinating disorders: The role of clinical, laboratory, imaging characteristics and peripheral blood type I interferon activity
by: Dimitris K. Karathanasis, et al.
Published: (2022-08-01)

Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022
by: Christoph Friedli, et al.
Published: (2022-12-01)

Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature
by: Aigli G. Vakrakou, et al.
Published: (2020-06-01)

Fatigue in Post-COVID-19 Syndrome: Clinical Phenomenology, Comorbidities and Association With Initial Course of COVID-19
by: Lara Diem MD, et al.
Published: (2022-05-01)

Rebound After Fingolimod and a Single Daclizumab Injection in a Patient Retrospectively Diagnosed With NMO Spectrum Disorder—MRI Apparent Diffusion Coefficient Maps in Differential Diagnosis of Demyelinating CNS Disorders
by: Franca Wagner, et al.
Published: (2018-09-01)

The utility of immunoglobulin A/complement 3 and immunoglobulin G/immunoglobulin M ratios in the assessment of disease activation in patients with Behçet disease
by: Didem Dincer, et al.
Published: (2021-04-01)

Immunoglobulin-resistant Kawasaki disease
by: Bibiana Marriaga-Núñez, et al.
Published: (2023-10-01)

Disease associated with immunoglobulin g
by: A G Chuchalin
Published: (2018-03-01)

The role of type I IFN in autoimmune and autoinflammatory diseases with CNS involvement
by: Sylvia Raftopoulou, et al.
Published: (2022-11-01)

Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson’s Disease Patients
by: Maximilianos Elkouris, et al.
Published: (2019-02-01)

Multiple Sclerosis immunotherapies and COVID-19 mortality: an analysis of the FDA Adverse Event Reporting System
by: Maximilian Pistor, et al.
Published: (2022-10-01)

Immunoglobulin Therapy in Inflammatory Bowel Disease
by: Douglas S Levine
Published: (1993-01-01)

The place of intravenous immunoglobulin in rheumatic diseases
by: N. V. Seredavkina, et al.
Published: (2016-01-01)

Immunoglobulin G4-related Disease
by: Sung-Hoon Moon
Published: (2023-12-01)

Intravenous Immunoglobulin Resistant Kawasaki Disease
by: Mohammad Reza Navaeifar, et al.
Published: (2013-01-01)

Intravenous Immunoglobulin Resistant Kawasaki Disease
by: Mohammad Reza Navaeifar, et al.
Published: (2013-01-01)